“We are excited to expand our gene therapy efforts to include targets in rare, inherited retinal diseases, for which there is tremendous unmet need. This partnership combines PTC’s strength in developing and commercializing treatments for rare diseases with Odylia’s novel vector platform and breadth of expertise in rare ophthalmic diseases”
— Mark Pykett, V.M.D., Ph.D., Chief Scientific Officer of PTC Therapeutics
Case Study Information to come soon.